Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06431373 · ClinicalTrials.gov registry record · Phase 3
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
A Phase 3 study of Uveitis and Uveitis, Posterior, sponsored by Priovant Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 371
- Enrollment target
- 20
- Study locations
NCT06431373 is a Phase 3 study of Uveitis and Uveitis, Posterior that is active but no longer recruiting, run by Priovant Therapeutics. The registered enrollment target is 371 participants, below the 598-participant average among 19 other Uveitis trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT06431373, a Phase 3 study of Uveitis and Uveitis, Posterior, is active but no longer recruiting, sponsored by Priovant Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 371 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
Conditions Studied
Interventions
- DRUG Brepocitinib PO QD
- DRUG Placebo PO QD
Study Locations (20)
California
- Clinical Trial Site - Bakersfield
- Clinical Trial Site - Beverly Hills
- Clinical Trial Site - Fullerton
- Clinical Trial Site - Irvine
- Clinical Trial Site - La Jolla
- Clinical Trial Site - Los Angeles
- Clinical Trial Site - Los Angeles
- Clinical Trial Site - Modesto
- Clinical Trial Site - Sacramento
Arizona
- Clinical Trial Site - Phoenix
- Clinical Trial Site - Phoenix
Colorado
- Clinical Trial Site - Aurora
- Clinical Trial Site - Denver
Florida
- Clinical Trial Site - Fort Lauderdale
- Clinical Trial Site - St. Petersburg
Illinois
- Clinical Trial Site - Chicago
- Clinical Trial Site - Oak Park
Indiana
- Clinical Trial Site - Carmel
Kansas
- Clinical Trial Site - Prairie Village
Maryland
- Clinical Trial Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2028-02-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06431373
The ClinicalTrials.gov registry entry for NCT06431373 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 371 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 598-participant average among 19 other Uveitis trials with a reported enrollment target (38% lower). The listed sponsor is Priovant Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Uveitis appearing as the primary indexed condition, and to 2 interventions - of which Brepocitinib PO QD is the first listed.
NCT06431373 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT06431373 about?
NCT06431373 is a clinical study titled "A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis". The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
What is the current status of trial NCT06431373?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 371 participants. The study started on 2024-09-11. Estimated completion is 2028-02-01.
What conditions does trial NCT06431373 study?
This clinical trial studies the following conditions: Uveitis, Uveitis, Posterior, Uveitis, Intermediate.
What interventions are being tested in trial NCT06431373?
The interventions under investigation include: Brepocitinib PO QD (DRUG), Placebo PO QD (DRUG).
Who is sponsoring clinical trial NCT06431373?
This trial is sponsored by Priovant Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06431373 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
RECRUITING · Phase 3
-
Study of Difluprednate in the Treatment of Uveitis
COMPLETED · Phase 3
-
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
COMPLETED · Phase 3
-
PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
COMPLETED · Phase 3
-
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
COMPLETED · Phase 3
-
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.